Table 2. Quality assessment and sub group analysis; HIV/AIDS and multi-drug resistance tuberculosis.
| Measure or Outcome | Study Characteristics (Number of Studies) | Summary OR | 95% CI | I2 |
| Outcome | Primary MDR-TB (7) | 2.28 | 1.52–3.04 | 0% |
| Secondary MDR-TB (9) | 1.02 | 0.80–1.24 | 17.9% | |
| Any (12) | 1.18 | 1.14–1.64 | 0% | |
| Type of study | Case-control (9) and cohort studies (1) | 1.20 | 0.79–1.58 | 0% |
| Cross sectional and Surveillance (18) | 1.26 | 1.02–1.49 | 33% | |
| Study base | Population (4) | 1.38 | 1.09–1.66 | 0% |
| Institution (24) | 1.20 | 0.96–1.43 | 19.6% | |
| Adjustment for | Demographic and tuberculosis related variables (10) | 1.51 | 1.02–1.99 | 0% |
| Demographic and socio-economic variables (8) | 1.33 | 0.7–1.96 | 0% | |
| Demographic,Tuberculosis and socio-economic related variables (8) | 1.23 | 0.96–1.56 | 54.3% | |
| Selection of control | from hospital and discharge records (7) | 1.39 | 0.80–1.99 | 0% |
| From population (2 study) | 2.53 | 0.65–4.42 | 0% |
I2 = percentage of total variance due to between- study heterogeneity.
OR = odd ratio of summary estimate.